2 terminated, 1 completed, 1 unknown, 1 withdrawn. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 2, Completed 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Albinism, Oculocutaneous: new trials by email Literature Review of Albinism, Oculocutaneous trials Research Report on Albinism, Oculocutaneous
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Pirfenidone Treatment in HPS-ILD Pirfenidone - Hermansky Pudlak Syndrome, Interstitial Lung Disease | Phase 2 | Unknown | Jesse Roman | 50 | 2019-12-01 | 2019-12-10 |
| Vision Response to Dopamine Replacement Levodopa/carbidopa - Albinism, Oculocutaneous Albinism | Phase 2 | Terminated | University of Wisconsin, Madison | 20 | 2012-10-17 | 2019-06-11 |
| Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome Mesalamine, Infliximab, Corticosteroids - Hermanski-Pudlak Syndrome, Colitis | Phase 2 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2007-08-07 | 2017-07-02 | |
| Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome Losartan, Zileuton, N-Acetylcysteine - Hermansky-Pudlak Syndrome (HPS), Pulmonary Fibrosis | Phase 1 / Phase 2 | Terminated | National Human Genome Research Institute (NHGRI) | 3 | 2007-04-01 | 2013-08-02 |
| Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome Pirfenidone, Placebo - Albinism, Inborn Errors of Metabolism | Phase 2 | Completed | William Gahl, M.D. | 35 | 2005-09-01 | 2017-10-16 |
Hermanski-Pudlak Syndrome (4) · Albinism (3) · Platelet Storage Pool Deficiency (2) · Pulmonary Fibrosis (2) · Colitis (1) · Lung Diseases (1) · Lung Diseases, Interstitial (1) · Metabolic Diseases (1) · Metabolism, Inborn Errors (1)
Amino Acid Metabolism, Inborn Errors (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Eye Diseases (5) · Eye Diseases, Hereditary (5) · Genetic Diseases, Inborn (5) · Hypopigmentation (5) · Nutritional and Metabolic Diseases (5) · Pigmentation Disorders (5) · Skin Diseases (5) · Skin Diseases, Genetic (5) · Skin and Connective Tissue Diseases (5) · Blood Coagulation Disorders (4) · Blood Coagulation Disorders, Inherited (4) · Blood Platelet Disorders (4) · Hematologic Diseases (4)
pirfenidone (2) · Acetylcysteine (1) · Adalimumab (1) · Adrenal Cortex Hormones (1) · Erythromycin (1) · Infliximab (1) · Losartan (1) · Mercaptopurine (1) · Mesalamine (1) · Pravastatin (1) · Tacrolimus (1) · carbidopa, levodopa drug combination (1) · zileuton (1)
Jesse Roman (1) · National Human Genome Research Institute (NHGRI) (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · University of Wisconsin, Madison (1) · William Gahl, M.D. (1)
United States (5) · Puerto Rico (1)
Jesse Roman, MD (1) · Michael C Struck, MD (1) · Thomas Markello, M.D. (1)